Race Oncology (ASX:RAC) has revealed the primary mechanism of action for its lead asset, (E,E)-bisantrene (RCDS1), in a discovery that reshapes how the drug could be developed and deployed in cancer care. …
Latest Video
New Stories
-
The challenge is for our gatekeepers. Can they see beyond the gate?
October 3, 2025 - - Latest News -
Trump administration links MFN and lower prices to faster FDA approvals
October 3, 2025 - - Latest News -
Vertex appoints Elisha Whitfield as senior country manager for Australia and New Zealand
October 2, 2025 - - Latest News -
Race Oncology uncovers novel anticancer mechanism for bisantrene
October 2, 2025 - - Australian Biotech -
Mark Butler announces boost for clinical trial reform, after years of delay
October 2, 2025 - - Latest News -
Pharmac moves to ease access to HIV medicines in New Zealand
October 2, 2025 - - Latest News -
If the UK has blinked on pharmaceutical pricing, Australia might have to pay attention
October 2, 2025 - - Latest News